Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 485071, 8 pages
http://dx.doi.org/10.1155/2015/485071
Review Article

The Role of Radiotherapy in Hodgkin’s Lymphoma: What Has Been Achieved during the Last 50 Years?

Department of Experimental Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2, 93-510 Lodz, Poland

Received 3 September 2014; Accepted 18 October 2014

Academic Editor: Vincent Ribrag

Copyright © 2015 Magdalena Witkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. King, M. T. Howard, and A. Bagg, “Hodgkin’s lymphoma: pathology, pathogenesis, and a plethora of potential prognostic predictors,” Advances in Anatomic Pathology, vol. 21, no. 1, pp. 12–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, France, 2008.
  4. J. M. Connors, “Clinical manifestations and natural history of Hodgkin's lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 124–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa, “ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2835–2841, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Engert, V. Diehl, J. Franklin et al., “Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4548–4554, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kewalramani, S. D. Nimer, A. D. Zelenetz et al., “Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 32, no. 7, pp. 673–679, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Engert, A. Plütschow, H. T. Eich et al., “Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma,” New England Journal of Medicine, vol. 363, no. 7, pp. 640–652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Hodgkin, “On some morbid appearances of the absorbent glands and spleen,” Medico-Chirurgical Transactions, vol. 17, pp. 68–114, 1832. View at Google Scholar
  10. W. A. Pusey, “Cases of sarcoma and Hodgkin’s disease treated by exposure to X-rays: preliminary report,” The Journal of the American Medical Association, vol. 38, pp. 166–169, 1902. View at Google Scholar
  11. R. Gilbert, “Notre methode de roentgentherapie de la lymphomagranulomatose (Hodgkin’s): resultats eloignes,” Acta Radiologica, vol. 12, 1931. View at Google Scholar
  12. L. S. Goodman and M. M. Wintrobe, “Nitrogen mustard therapy; use of methyl- bis (beta-chloroethyl) amine hydrochloride and tris (beta- chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders,” The Journal of the American Medical Association, vol. 132, pp. 126–132, 1946. View at Google Scholar
  13. L. K. Alpert and S. S. Peterson, “The use of nitrogen mustard in the treatment of lymphomata,” Bulletin of the U.S. Army Medical Department, vol. 7, no. 2, pp. 187–194, 1947. View at Google Scholar
  14. V. T. Devita Jr., A. A. Serpick, and P. P. Carbone, “Combination chemotherapy in the treatment of advanced Hodgkin's disease,” Annals of Internal Medicine, vol. 73, no. 6, pp. 881–895, 1970. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Bonadonna, P. Valagussa, A. Santoro, S. Viviani, V. Bonfante, and A. Banfi, “Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVD,” Recent Results in Cancer Research, vol. 117, pp. 169–174, 1989. View at Google Scholar · View at Scopus
  16. M. A. Petres, “A study of survival in Hodgkin's disease treated radiologically,” American Journal of Roentgenology, vol. 63, pp. 299–311, 1950. View at Google Scholar
  17. H. Kaplan, “The radical radiotherapy of regionally localized Hodgkin's disease,” Radiology, vol. 78, pp. 553–561, 1962. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Hoskin, P. Smith, T. S. Maughan et al., “Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma,” Clinical Oncology, vol. 17, no. 1, pp. 47–53, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Eichenauer, A. Engert, and M. Dreyling, “Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 22, no. 6, pp. vi55–vi58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Rosenberg and H. S. Kaplan, “Evidence for an orderly progression in the spread of Hodgkin's disease,” Cancer Research, vol. 26, no. 6, pp. 1225–1231, 1966. View at Google Scholar · View at Scopus
  21. H. S. Kaplan, “Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas,” New England Journal of Medicine, vol. 278, no. 16, pp. 892–899, 1968. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Castellino, A. M. Geiger, A. C. Mertens et al., “Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood cancer survivor study,” Blood, vol. 117, no. 6, pp. 1806–1816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Bhatia, N. K. C. Ramsay, J. P. Bantle, A. Mertens, and L. L. Robison, “Thyroid abnormalities after therapy for hodgkin's disease in childhood,” Oncologist, vol. 1, no. 1-2, pp. 62–67, 1996. View at Google Scholar · View at Scopus
  24. M. M. Hudson, C. A. Poquette, J. Lee et al., “Increased mortality after successful treatment for Hodgkin's disease,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3592–3600, 1998. View at Google Scholar · View at Scopus
  25. S. L. Hancock, M. A. Tucker, and R. T. Hoppe, “Factors affecting late mortality from heart disease after treatment of Hodgkin's disease,” Journal of the American Medical Association, vol. 270, no. 16, pp. 1949–1955, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Mulrooney, M. W. Yeazel, T. Kawashima et al., “Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort,” BMJ (Online), vol. 339, no. 7736, Article ID b4606, p. 34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. C. Hodgson, E. S. Gilbert, G. M. Dores et al., “Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1489–1497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. B. Travis, D. Hill, G. M. Dores et al., “Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma,” Journal of the National Cancer Institute, vol. 97, no. 19, pp. 1428–1437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Swerdlow, R. Cooke, A. Bates et al., “Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2745–2752, 2012. View at Publisher · View at Google Scholar
  30. J. F. Abrahamsen, A. Andersen, E. Hannisdal et al., “Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age,” Journal of Clinical Oncology, vol. 11, no. 2, pp. 255–261, 1993. View at Google Scholar · View at Scopus
  31. M. Z. Koontz, S. J. Horning, R. Balise et al., “Risk of therapy-related secondary leukemia in hodgkin lymphoma: the stanford university experience over three generations of clinical trials,” Journal of Clinical Oncology, vol. 31, no. 5, pp. 592–598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Valagussa and G. Bonadonna, “Hodgkin's disease and second malignancies,” Annals of Oncology, vol. 4, no. 2, pp. 94–95, 1993. View at Google Scholar · View at Scopus
  33. G. P. Canellos, J. S. Abramson, D. C. Fisher, and A. S. LaCasce, “Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1611–1615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. R. M. Meyer, M. K. Gospodarowicz, J. M. Connors et al., “ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma,” New England Journal of Medicine, vol. 366, no. 5, pp. 399–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. M. Raemaekers, M. P. E. André, M. Federico et al., “Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin’s lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial,” Journal of Clinical Oncology, vol. 32, no. 12, pp. 1188–1194, 2014. View at Google Scholar
  36. A. Engert, H. Haverkamp, C. Kobe et al., “Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial,” The Lancet, vol. 379, no. 9828, pp. 1791–1799, 2012. View at Publisher · View at Google Scholar
  37. S. L. Wolden, L. Chen, K. M. Kelly et al., “Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma—a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 30, no. 26, pp. 3174–3180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Kahn, C. Flowers, Z. Xu, and N. Esiashvili, “Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 1, pp. 175–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. R. Halie, J. J. Seldenrath, H. C. Stam, and H. O. Nieweg, “Curative radiotherapy in Hodgkin's disease: significance of haematogenous dissemination established by examination of peripheral blood and spleen,” The British Medical Journal, vol. 2, no. 5814, pp. 611–613, 1972. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Engert, P. Schiller, A. Josting et al., “Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group,” Journal of Clinical Oncology, vol. 21, no. 19, pp. 3601–3608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. D. C. Weber, N. Peguret, G. Dipasquale, and L. Cozzi, “Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin’s lymphoma: a comparative planning study,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 5, pp. 1578–1586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. B. A. Campbell, N. Voss, T. Pickles et al., “Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5170–5174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Girinsky, C. Pichenot, A. Beaudre, M. Ghalibafian, and D. Lefkopoulos, “Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?” International Journal of Radiation Oncology, Biology, Physics, vol. 64, no. 1, pp. 218–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Koeck, Y. Abo-Madyan, F. Lohr et al., “Radiotherapy for early mediastinal hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 1, pp. 268–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. G. S. Mageras and E. Yorke, “Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment,” Seminars in Radiation Oncology, vol. 14, no. 1, pp. 65–75, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Paumier, M. Ghalibafian, J. Gilmore et al., “Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 4, pp. 1522–1527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. M. T. Vlachaki and S. Kumar, “Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease—a feasibility study,” Journal of Applied Clinical Medical Physics, vol. 11, no. 1, p. 3042, 2010. View at Google Scholar · View at Scopus
  48. C. Chargari, S. Zefkili, and Y. M. Kirova, “Potential of helical tomotherapy for sparing critical organs in a patient with AIDS who was treated for Hodgkin lymphoma,” Clinical Infectious Diseases, vol. 48, no. 5, pp. 687–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. M. Kirova, C. Chargari, M. Amessis, J.-P. Vernant, and N. Dhedin, “Concurrent involved field radiation therapy and Temsirolimus in refractory mantle cell lymphoma (MCL),” American Journal of Hematology, vol. 85, no. 11, p. 892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. K. W. McCutchen, J. M. Watkins, P. Eberts, L. E. Terwilliger, M. S. Ashenafi, and J. M. Jenrette, “Helical tomotherapy for total lymphoid irradiation,” Radiation Medicine—Medical Imaging and Radiation Oncology, vol. 26, no. 10, pp. 622–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Miralbell, A. Lomax, L. Cella, and U. Schneider, “Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors,” International Journal of Radiation Oncology, Biology, Physics, vol. 54, no. 3, pp. 824–829, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. P. J. Taddei, A. Mahajan, D. Mirkovic et al., “Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation,” Physics in Medicine and Biology, vol. 55, no. 23, pp. 7067–7080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. W. D. Newhauser, J. D. Fontenot, A. Mahajan et al., “The risk of developing a second cancer after receiving craniospinal proton irradiation,” Physics in Medicine and Biology, vol. 54, no. 8, pp. 2277–2291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Li, B. Dabaja, V. Reed et al., “Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma,” International Journal of Radiation Oncology Biology Physics, vol. 81, no. 1, pp. 167–174, 2011. View at Publisher · View at Google Scholar · View at Scopus